Intradigm Corporation

Rockville, MD 20852

SBIR Award Summary

Total Number of Awards 4
Total Value of Awards $424K
First Award Date 05/12/04
Most Recent Award Date 08/01/05

Key Personnel

Last Name Name Awards Contact
Mixson Archibald James Mixson 1
Scaria Puthupparampil V Scaria 1
Tang Qingquan Tang 1
Xie Frank Y Xie 1

4 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 08/01/05 - 01/31/08

DESCRIPTION (provided by applicant): We are proposing this project to develop and commercialize a novel, histidine/lysine (HK) polymer based, siRNA transfection reagent. The goal of the phase I study of this project is to evaluate the feasibility of using PT88, a member of the HK polymer family, as siRNA transfection reagent. RNA interference ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 07/01/04 - 06/30/05

DESCRIPTION (provided by applicant): The objective of this proposal is to evaluate using siRNA agent to knockdown pro-angiogenic genes as a treatment for HSV infection of eyes that can result the blinding lesions of stromal keratitis (SK). Recurrence of herpes simplex virus (HSV) infection is the most common infectious cause of corneal blindness...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic:
Budget: 06/01/04 - 11/30/05

DESCRIPTION (provided by applicant): Angiogenesis of solid tumors is an important target of cancer therapy. It has been well recognized that growth and metastasis of solid tumors require persistent angiogenesis and that induction of angiogenesis is a discrete component of the tumor phenotype. Vascular endothelial growth factor and its cognate r...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 05/12/04 - 04/30/05

DESCRIPTION (provided by applicant): A systemic targetable vector system is extremely important for the success and broader application of nucleic acids based therapeutics such as gene therapy, antisense therapy, and the emerging field of RNA interference. Systemic targeting has been a challenge not only for macromolecular drugs such as DNA, but...